Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.81 USD | +6.79% | -0.23% | +60.47% |
May. 07 | Transcript : Inogen, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Earnings Flash (INGN) INOGEN Posts Q1 Revenue $78M, vs. Street Est of $73.7M | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The stock, which is currently worth 2024 to 0.35 times its sales, is clearly overvalued in comparison with peers.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+60.47% | 195M | B | ||
-5.56% | 181B | C+ | ||
-0.11% | 108B | C | ||
-6.17% | 66.57B | A | ||
+2.64% | 49.95B | B- | ||
+6.58% | 43.84B | B- | ||
+4.91% | 41.71B | B+ | ||
+21.98% | 31.59B | B | ||
+14.45% | 25.3B | A- | ||
-5.81% | 23.94B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- INGN Stock
- Ratings Inogen, Inc.